PL348575A1 - Controlled release formulation comprising gnrh-ii - Google Patents

Controlled release formulation comprising gnrh-ii

Info

Publication number
PL348575A1
PL348575A1 PL99348575A PL34857599A PL348575A1 PL 348575 A1 PL348575 A1 PL 348575A1 PL 99348575 A PL99348575 A PL 99348575A PL 34857599 A PL34857599 A PL 34857599A PL 348575 A1 PL348575 A1 PL 348575A1
Authority
PL
Poland
Prior art keywords
gnrh
controlled release
release formulation
formulation
controlled
Prior art date
Application number
PL99348575A
Inventor
Steve Qi
Karen Akinsanya
Amanda Hayward
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of PL348575A1 publication Critical patent/PL348575A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL99348575A 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii PL348575A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9826662A GB2344287A (en) 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation
PCT/GB1999/004045 WO2000032218A1 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii

Publications (1)

Publication Number Publication Date
PL348575A1 true PL348575A1 (en) 2002-06-03

Family

ID=10843631

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99348575A PL348575A1 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii

Country Status (22)

Country Link
EP (1) EP1140133A1 (en)
JP (1) JP2002531411A (en)
KR (1) KR20010089538A (en)
CN (1) CN1332635A (en)
AU (1) AU770676B2 (en)
BR (1) BR9915943A (en)
CA (1) CA2353798A1 (en)
CZ (1) CZ20011893A3 (en)
EE (1) EE200100293A (en)
GB (1) GB2344287A (en)
HR (1) HRP20010421A2 (en)
HU (1) HUP0104943A3 (en)
IL (1) IL143496A0 (en)
MX (1) MXPA01005543A (en)
NO (1) NO20012636L (en)
NZ (1) NZ511984A (en)
PL (1) PL348575A1 (en)
RU (1) RU2233170C2 (en)
SK (1) SK7552001A3 (en)
TR (1) TR200102273T2 (en)
WO (1) WO2000032218A1 (en)
ZA (1) ZA200104530B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007012430A1 (en) * 2005-07-26 2007-02-01 Georg-August-Universität-Göttingen Method for induction and enhancement of apoptosis in tumor cells
GB0616111D0 (en) 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2411038B1 (en) 2009-03-27 2016-12-28 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
WO2011056572A1 (en) 2009-10-27 2011-05-12 The Board Of Trustees Of The University Of Illinois Methods of diagnosing diastolic dysfunction
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
IN2012DN06437A (en) 2010-01-27 2015-10-09 Univ Indiana Res & Tech Corp
WO2011116026A2 (en) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibitors of beta integrin-g protein alpha subunit binding interactions
JP5969469B2 (en) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Single-chain insulin agonist with high activity for insulin receptor
US20120004182A1 (en) 2010-07-02 2012-01-05 Carsten Gruendker Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
JP6086067B2 (en) 2010-12-22 2017-03-01 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Glucagon analog showing GIP receptor activity
CN103857408B (en) 2011-06-22 2017-04-12 印第安那大学科技研究公司 Glucagon/glp-1 receptor co-agonists
WO2013055791A1 (en) 2011-10-10 2013-04-18 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
MX2014003579A (en) 2011-11-17 2015-04-10 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting glucocorticoid receptor activity.
WO2013096386A1 (en) 2011-12-20 2013-06-27 Indiana University Research And Technology Corporation Ctp-based insulin analogs for treatment of diabetes
CN104619350A (en) 2012-06-14 2015-05-13 Ambrx公司 Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
MY185217A (en) 2012-06-21 2021-04-30 Hoffmann La Roche Analogs of glucagon exhibiting gip receptor activity
AR091477A1 (en) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp GLUCAGON ANALOGS PRESENTING GIP RECEIVER ACTIVITY
US9593156B2 (en) 2012-09-26 2017-03-14 Indiana University Research And Technology Corporation Insulin analog dimers
RU2678134C2 (en) 2013-03-14 2019-01-23 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Insulin-incretin conjugates
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
ES2822994T3 (en) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Incretin-insulin conjugates
JP6912386B2 (en) 2015-01-26 2021-08-04 ザ ユニバーシティー オブ シカゴ CAR T cells that recognize cancer-specific IL13Rα2
JP7264592B2 (en) 2015-01-26 2023-04-25 ザ ユニバーシティー オブ シカゴ IL13Rα2 BINDING AGENTS AND THEIR USE IN CANCER THERAPY
CN104789524A (en) * 2015-04-30 2015-07-22 四川大学 Osteoporotic rat primary osteoblasts isolated culture method and application thereof
US20180201937A1 (en) 2015-08-04 2018-07-19 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
JP2020505379A (en) * 2017-01-20 2020-02-20 イミューン システム レギュレェイション ホールディング エービー Novel compound (immunorelin)
CN110996953A (en) 2017-06-30 2020-04-10 安进公司 Method for treating heart failure with activators of the cardiac sarcomere
PL3661954T3 (en) 2017-08-03 2022-05-16 Amgen Inc. INTERLEUKIN 21 MUTEINS AND TREATMENT
ES2985118T3 (en) 2017-09-08 2024-11-04 Amgen Inc KRAS G12C inhibitors and methods of using them
HUE067603T2 (en) 2017-09-18 2024-10-28 Univ California Claudin6 antibodies and methods of treating cancer
TW201930344A (en) 2018-01-12 2019-08-01 美商安進公司 Anti-PD-1 antibodies and methods of treatment
US20200085776A1 (en) 2018-09-10 2020-03-19 Cardax, Inc. Methods of Reducing C-Reactive Protein and/or Treating Cardiovascular Disease
JP7682797B2 (en) 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Claudin 6 Bispecific Antibody
EP4527408A3 (en) 2019-03-20 2025-06-25 The Regents of the University of California Claudin-6 antibodies and drug conjugates
AU2019437315B2 (en) * 2019-03-26 2022-10-06 Novel Pharma Inc. Long-acting fatty acid-binding GnRH derivative and pharmaceutical composition comprising same
EP3952841A1 (en) 2019-04-09 2022-02-16 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
US20230190725A1 (en) 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
US20220195059A1 (en) 2019-04-30 2022-06-23 Instituto de Medicina Molecular João Lobo Antunes Rank Pathway Inhibitors in Combination with CDK Inhibitors
MX2021015937A (en) 2019-06-24 2022-02-03 Amgen Inc Inhibition of sirp-gamma for cancer treatment.
WO2021042048A1 (en) 2019-08-30 2021-03-04 Research Institute At Nationwide Children's Hospital Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
AU2021380754A1 (en) 2020-11-12 2023-06-22 Amgen Inc. Methods of treating heart failure by administering omecamtiv mecarbil
JP2024504696A (en) 2021-01-20 2024-02-01 バイオアントレ エルエルシー CTLA4-binding proteins and methods of treating cancer
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (en) * 1983-09-23 1987-07-15 Debiopharm Sa PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES.
DE3414595A1 (en) * 1984-04-18 1985-10-31 Hoechst Ag, 6230 Frankfurt USE OF GONADOLIBERIN AND GONADOLIBERINAGONISTS FOR TREATING CLIMATE COMPLAINTS
US4540513A (en) * 1984-09-25 1985-09-10 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Decapeptide having gonadotropin releasing activity
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
DE3634435A1 (en) * 1986-10-09 1988-04-14 Hoechst Ag ANALOGA OF GONADOLIBERIN WITH IMPROVED SOLUBILITY, METHOD FOR THE PRODUCTION THEREOF, THE CONTAINERS THEREOF AND THEIR USE
NO302481B1 (en) * 1990-10-16 1998-03-09 Takeda Chemical Industries Ltd Polymer for an extended release preparation, as well as an extended release preparation
IT1243390B (en) * 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
WO1997047743A1 (en) * 1996-06-13 1997-12-18 Zymogenetics, Inc. Human type ii gonadotropin-releasing hormone receptor
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
GB2343182A (en) * 1998-10-27 2000-05-03 Ferring Bv Use of GnRH-II and analogues thereof for the treatment of osteoporosis

Also Published As

Publication number Publication date
CA2353798A1 (en) 2000-06-08
HRP20010421A2 (en) 2002-06-30
HUP0104943A2 (en) 2002-06-29
GB2344287A (en) 2000-06-07
TR200102273T2 (en) 2001-12-21
EE200100293A (en) 2002-08-15
HUP0104943A3 (en) 2002-08-28
MXPA01005543A (en) 2003-07-14
IL143496A0 (en) 2002-04-21
GB9826662D0 (en) 1999-01-27
KR20010089538A (en) 2001-10-06
NO20012636L (en) 2001-07-12
CN1332635A (en) 2002-01-23
WO2000032218A1 (en) 2000-06-08
EP1140133A1 (en) 2001-10-10
RU2233170C2 (en) 2004-07-27
ZA200104530B (en) 2002-06-04
JP2002531411A (en) 2002-09-24
NO20012636D0 (en) 2001-05-29
CZ20011893A3 (en) 2002-05-15
BR9915943A (en) 2001-08-21
AU1573200A (en) 2000-06-19
NZ511984A (en) 2002-11-26
SK7552001A3 (en) 2002-02-05
AU770676B2 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
IL143496A0 (en) Controlled release formulation comprising gnrh-ii
EG24198A (en) Extended release formulation
SG71879A1 (en) Controlled release compositions
SG93831A1 (en) Polimeric controlled release compositions
PL343021A1 (en) Formulations
PL346423A1 (en) Microcapsule formulations
SG71789A1 (en) Controlled release compositions
EG24226A (en) Formulation
IL135457A0 (en) Extended release formulation
PL346414A1 (en) Microcapsule formulations
SG72947A1 (en) Controlled release compositions
GB9905898D0 (en) Controlled-dose formulation
GB9902304D0 (en) Formulation
AUPP279698A0 (en) Sustained release formulation
GB2334486B (en) Release unit
GB2322867B (en) Release agent
GB9810180D0 (en) Novel formulation
GB9815002D0 (en) Formulations
GB9927614D0 (en) Sterliant formulation
GB9815001D0 (en) Formulations
GB9711946D0 (en) Release devices
GB9816563D0 (en) Controlled release formulations
GB9404544D0 (en) Controlled release formulation
GB9902236D0 (en) Formulation
GB9916958D0 (en) Controlled release formulations

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)